Theranica, a neuromodulation therapeutics company advancing migraine care through its proprietary Remote Electrical Neuromodulation (REN) technology, announced results from the largest and longest-running real-world evidence study of migraine treatment in the U.S. veteran population published to date. The peer-reviewed study, published in Military Medicine, the official journal of AMSUS – the Society of Federal Health Professionals, found that Nerivio, the company’s FDA-cleared REN wearable, gave veterans consistent, patient-centered relief from migraine while reducing their reliance on prescribed migraine medications.

The prospective real-world evidence study, conducted in accordance with the FDA’s Real-World Evidence framework, followed 466 veterans cared for by the Veterans Health Administration (VHA) across 28,274 REN treatments between November 2020 and February 2026. It was co-authored by neurologists from VHA Headache Centers of Excellence in Nashville, TN and Chicago, IL, the Central Virginia VA Health Care System and Virginia Commonwealth University, and the VA Connecticut Healthcare System, alongside Theranica’s medical information and research team. The study’s multi-site authorship reflects REN’s existing clinical integration across several VHA Headache Centers of Excellence nationwide.